利福昔明对慢性活动性肝炎和代偿期肝硬化肠源性内毒素血症及肝脏炎症的影响  

Effects of Rifaximin on Intestinal Endotoxemia and Liver Inflammation in Chronic Active Hepatitis and Compensated Cirrhosis

作　　者：田瑞民[1] TIAN Rui-min(Department of Emergency,Tianjin Second People's Hospital,Tianjin 300110,China)

机构地区：[1]天津市第二人民医院急诊科,天津300110

出　　处：《医学信息》2023年第9期90-93,共4页Journal of Medical Information

摘　　要：目的研究利福昔明对慢性活动性肝炎和代偿期肝硬化肠源性内毒素血症及肝脏炎症的影响。方法选取2021年5月-2022年3月在我院治疗的114例慢性活动性肝炎和代偿期肝硬化肠源性内毒素血症患者为研究对象,采用随机数字表法分为对照组(n=57)和观察组(n=57)。对照组采用常规保肝治疗,观察组在对照组基础上给予利福昔明治疗。比较两组临床疗效、肝功能指标、炎症因子水平、血清内毒素水平以及不良反应发生情况。结果观察组治疗总有效率为94.74%,高于对照组的80.70%(P<0.05);两组治疗后谷丙转氨酶(ALT)、总胆红素(TBIL)均低于治疗前,白蛋白(ALB)均高于治疗前,且观察组ALT、TBIL低于对照组,ALB高于对照组(P<0.05);两组治疗后肿瘤坏死因子-α(TNF-α)、白介素-1(IL-6)水平均低于治疗前,且观察组低于对照组(P<0.05);两组治疗后血清内毒素水平均低于治疗前,且观察组低于对照组(P<0.05);观察组不良反应发生率为8.77%,与对照组的7.02%比较,差异无统计学意义(P>0.05)。结论利福昔明对慢性活动性肝炎和代偿期肝硬化肠源性内毒素血症具有一定的疗效,可提高治疗总有效率,降低内毒素水平,抑制炎症反应,纠正肝功能指标,且不会增加不良反应,具有缓解肝脏炎症的重要作用。Objective To study the effect of rifaximin on intestinal endotoxemia and liver inflammation in chronic active hepatitis and compensated cirrhosis.Methods From May 2021 to March 2022,114 patients with chronic active hepatitis and compensated cirrhosis intestinal endotoxemia treated in our hospital were selected as the research objects.They were divided into control group(n=57)and observation group(n=57)by random number table method.The control group was treated with conventional liver protection therapy,and the observation group was treated with rifaximin on the basis of the control group.The clinical efficacy,liver function index,inflammatory factor level,serum endotoxin level and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 94.74%,which was higher than 80.70%of the control group(P<0.05).After treatment,alanine aminotransferase(ALT)and total bilirubin(TBIL)in the two groups were lower than those before treatment,and albumin(ALB)was higher than that before treatment,while ALT and TBIL in the observation group were lower than those in the control group,and ALB was higher than that in the control group(P<0.05).After treatment,the levels of tumor necrosis factor-α(TNF-α)and interleukin-1(IL-6)in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P<0.05).The serum endotoxin levels of the two groups after treatment were lower than those before treatment,and the observation group was lower than the control group(P<0.05).The incidence of adverse reactions in the observation group was 8.77%,which was compared with 7.02%in the control group,the difference was not statistically significant(P>0.05).Conclusion Rifaximin has a certain effect on chronic active hepatitis and intestinal endotoxemia in compensated cirrhosis,which can improve the total effective rate of treatment,reduce the level of endotoxin,inhibit the inflammatory response,correct the liver function index,and

关 键 词：利福昔明 慢性活动性肝炎 内毒素血症 肝脏炎症 

分 类 号：R575.2[医药卫生—消化系统]